Key result
Optimized immunosuppressive therapy completely resolves rheumatoid arthritis-associated pseudochylothorax.
Why the study?
Differentiating chylothorax from pseudochylothorax is essential due to their distinct etiologies, clinical implications, and management strategies.
Case Report (n=1)
Cholesterol crystal identification in pleural fluid can confirm a diagnosis of pseudochylothorax even when cholesterol levels are lower than traditional thresholds, allowing for successful conservative management through optimization of underlying rheumatoid arthritis treatment.
Supports lipid analysis for pseudochylothorax diagnosis in RA; leaves open generalizability and optimal thresholds pending larger studies.
Chylothorax and pseudochylothorax are both rare forms of pleural effusion characterized by a milky appearance of the pleural fluid. Despite their similarities, they have distinct etiologies, clinical implications, and medical management strategies. Pleural fluid analysis of cholesterol and triglyceride levels is crucial to differentiate between them, establish a proper diagnosis, and guide clinical evaluation and treatment. This case report describes an uncommon presentation of pseudochylothorax associated with long‐standing rheumatoid arthritis (RA) in a patient with no prior history of pleural disease.
No takes yet. Share an insight, caveat, or question.
Pizarro-Peña et al. (2026) conducted a case report in Pseudochylothorax associated with rheumatoid arthritis (n=1). Targeted rheumatoid arthritis therapy (methotrexate and adalimumab) was evaluated on Resolution of respiratory symptoms and pleural effusion. Pleural fluid analysis showing cholesterol crystals and low triglycerides confirmed pseudochylothorax in an 82-year-old RA patient, resolving completely with optimized immunosuppressive therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: